Group 1 - Pang Donglai Group has announced the establishment of an "Open Day" for better public understanding and learning about the company, with a fee of 20,000 yuan per person [2] - Chery Group's Zongheng G700 has officially launched, featuring amphibious capabilities with a price range of 304,900 to 389,900 yuan, and a special amphibious version priced at 700,000 yuan [3] - China's overseas box office revenue for films has reached 140 million USD (approximately 1 billion yuan) by October 20, 2025, surpassing the total for 2024, with 46 countries involved in screenings [4] Group 2 - Beijing has reported the highest import value of rare disease medications in the country, totaling 2.66 billion yuan in the first eight months of 2025, marking a 59.1% increase [5] - Sichuan's GDP for the first three quarters of 2025 has grown by 5.5%, reaching 4.932 trillion yuan [6] - The Export-Import Bank has indicated that 40% of new policy financial tools are directed towards projects in the digital economy and artificial intelligence sectors [8] Group 3 - The 2025 North Bund International Shipping Forum has released over 50 industry achievements, the highest in its history, to enhance China's integration into global shipping governance [9] - Kweichow Moutai has refuted rumors about plans to open 650 new specialty stores, emphasizing the need for market rationality [10] - China's trust industry has surpassed 30 trillion yuan in asset management scale, reaching 32.43 trillion yuan as of June 2025, with a year-on-year growth of 20.11% [11] Group 4 - Guizhou Province is promoting the development of diverse financial products and services tailored to consumer characteristics, encouraging collaboration between financial institutions and businesses [12] - A breakthrough in oral insulin delivery has been achieved by a research team, providing new hope for diabetes patients [13]

（原标题：我国胰岛素口服递送取得新突破；脑机接口企业使失明患者恢复视力） 这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 国家药监局：加大医疗器械研发创新支持力度 加快创新产品上市步伐 10月21日，由国家药监局南方医药经济研究所主办的"2025医疗器械经济信息发布会"在合肥召开。会议 指出，国家药监局将进一步完善法律标准体系，加大研发创新支持力度，提高审评审批质效，全方位筑 牢医疗器械高水平安全底线，加快创新产品上市步伐，促进医疗器械产业创新高质量发展。 10月21日，国药股份(600511.SH)公告称，国药股份发布2025年第三季度报告，第三季度公司实现营业 收入137.47亿元，同比增长3.58%；归属于上市公司股东的净利润为5.44亿元，同比增长13.10%。 资本市场 药械审批 圣因生物靶向C3 siRNA药物SGB-9768获FDA孤儿药资格认定 10月21日，圣因生物（SanegeneBio）宣布，其自主研发的靶向补体C3的siRNA药物SGB-9768注射液近 日获得美国食品药品监督管理局（FDA）孤儿药资格认定（Orphan Drug ...

陈军歌表示，这一智能化牛奶外泌体递送系统，借助"三级导航"机制实现了胰岛素的精准递送，为口服 大分子药物的研发设立了新标杆。该技术具备显著的临床转化潜力，不仅有望让糖尿病患者告别每天打 针的痛苦，提高治疗依从性与生活质量，也为其他生物大分子药物的口服递送提供了新思路。目前，研 究团队正致力于该技术的进一步优化及临床转化研究。 目前，全球有超过8亿糖尿病患者需依赖胰岛素治疗。主流治疗方式为皮下注射，不仅给患者带来身体 疼痛与心理负担，还可能引发局部感染和低血糖等副作用。陈军歌指出："胰岛素口服给药是一个世界 级难题，必须突破胃肠道中的三个难关——胃酸与蛋白酶对胰岛素的降解、肠道上皮细胞对大分子药物 的阻隔，以及胰岛素入血后被肝脏快速代谢的问题。" 研究团队从牛奶中获得灵感，通过膜融合技术将牛奶外泌体与智能响应型脂质体结合，构建出新型智能 化牛奶外泌体。该系统既保留了牛奶外泌体的天然稳定性，又具备智能响应能力，可如同"多功能快递 员"般突破口服药物的多重阻碍。 实验结果显示，MiNVs可将胰岛素的口服生物利用度提升至20.4%，是传统口服制剂的20倍以上，已达 到临床应用标准。在猪糖尿病模型中，口服MiNVs后2 ...